7-[4-(4-Fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-YL]-3,5-dihydroxy-heptanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-[4-(4-Fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-YL]-3,5-dihydroxy-heptanoic acid
• 英文别名: (3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyheptanoic acid
• 化学式: C₂₂H₃₀FN₃O₆S
• 分子量: 483.6
• InChiKey: ZVPAUNJUMAQCNK-IAGOWNOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases
  申请人：Nycomed GmbH

  公开号：EP2359826A1

  公开（公告）日：2011-08-24

  The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.

  本发明涉及将 PDE4 抑制剂与 HMG-CoA 还原酶抑制剂联合用于预防和治疗炎症性肺病，其中 PDE4 抑制剂选自 ROFLUMILAST、ROFLUMILAST 的药学上可接受的盐、ROFLUMILAST-N-氧化物和 ROFLUMILAST-N-oxide 的药学上可接受的盐组成的组，HMG-CoA 还原酶抑制剂为 ROSUVASTATIN 或其药学上可接受的盐。
• Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
  申请人：Nycomed GmbH

  公开号：EP2363130A1

  公开（公告）日：2011-09-07

  The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.

  本发明涉及联合使用 PDE4 抑制剂和 HMG-CoA 还原酶抑制剂来预防和治疗炎症性肺病。
• Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
  申请人：Takeda GmbH

  公开号：EP2359826B1

  公开（公告）日：2013-10-30
• Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease
  申请人：Wollin Stefan-Lutz

  公开号：US20100069392A1

  公开（公告）日：2010-03-18

  The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.
• COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
  申请人：TAKEDA GMBH

  公开号：US20150272949A1

  公开（公告）日：2015-10-01

  The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the prevention and curative treatment of an inflammatory pulmonary disease.